Singapore, Nov. 26 -- Singapore headquartered Prestige Biopharma, a biopharmaceutical company specialising in antibody therapeutics, has announced an exclusive license and supply agreement with Biosidus, a biotechnology company headquartered in Buenos Aires, Argentina, with decades of experience in biosimilar development and commercialisation, for the commercialisation of Tuznue(R) (trastuzumab) across Latin American markets, including Argentina, Mexico, Bolivia, and Paraguay.

Tuznue(R) is a biosimilar to Herceptin(R) (trastuzumab), approved for the treatment of breast cancer and metastatic gastric cancer. Prestige Biopharma received European Commission (EC) marketing authorisation for Tuznue(R) in September 2024. This approval marks a m...